A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
about
The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including AtherosclerosisInflammation and α-synuclein's prion-like behavior in Parkinson's disease--is there a link?The expression levels of prolyl oligopeptidase responds not only to neuroinflammation but also to systemic inflammation upon liver failure in rat models and cirrhotic patientsCharacterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease.Inhibition by Multifunctional Magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease ModelNurr1-Based Therapies for Parkinson's Disease.Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy.The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases.Altered peptidase activities in thyroid neoplasia and hyperplasia.Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model.Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerationsPeptide POP inhibitors for the treatment of the cognitive symptoms of schizophrenia.Animal models of Parkinson's disease: a gateway to therapeutics?Epigenome-Wide Association Study of Aggressive Behavior.Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.An update on potential therapeutic strategies for Parkinson's disease based on pathogenic mechanisms.Prolyl oligopeptidase and dipeptidyl peptidase II/dipeptidyl peptidase IV ratio in the cerebrospinal fluid in Parkinson's disease: historical overview and future prospects.Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interactionAnalyzing slowly exchanging protein conformations by ion mobility mass spectrometry: study of the dynamic equilibrium of prolyl oligopeptidase.New compounds identified through in silico approaches reduce the α-synuclein expression by inhibiting prolyl oligopeptidase in vitro.Unveiling prolyl oligopeptidase ligand migration by comprehensive computational techniques.Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?Dynamics and ligand-induced conformational changes in human prolyl oligopeptidase analyzed by hydrogen/deuterium exchange mass spectrometryRemoval of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.Active-Site-Directed Inhibitors of Prolyl Oligopeptidase Abolish Its Conformational Dynamics.
P2860
Q26795473-F20CFA96-4F72-48B4-9A7D-BD8C9250F4AAQ27022728-B9F0EBB9-2C16-41FA-9C1C-C5B5FB9364EDQ28607060-2C2A5D63-0F1D-4DA5-A8F2-19563318A536Q35054395-F63AAB22-F43B-4C64-9D2A-CE8C738297ECQ36237308-962DFEA2-22B0-4A8C-8B70-3ECDC3A20E39Q36803630-8BC385A7-C61C-4A00-B064-737CDC69C054Q37213903-1D49F3BC-5C55-492F-B577-7530913DDBB7Q37278592-6F566DE4-46DE-4700-8CCF-46126DAD4D99Q37385621-083330EA-91EE-4E3B-B9F3-C50F53A8A727Q37472054-201326EF-A872-4610-9CAF-E4E00DECDA26Q37566684-E7CAAC68-F044-41D1-9F44-D2F827018810Q38136309-2D8F38C7-0614-468E-B340-9125605DD46EQ38155480-A9CC2BA1-2B1B-4FF0-9F2F-9D2ECCF7DDDEQ38455757-2ED8599D-1E21-4AA2-AB01-06EE2BA98FEBQ38668992-EE7D71B0-2830-4BC8-934E-18444E92D1ABQ38821744-ED459C46-5C41-46A9-AF7C-CD6D7D29E066Q38823785-F6DBFFF0-F887-428E-9490-5041AC563160Q38833194-1DFC1C49-B03D-4EB6-AAA8-585C29D0EC91Q38923732-7B2B231C-4484-4A89-9BFC-8B8D55903AD3Q39584678-31E3FDF8-D152-4434-9E04-12E79F1DA525Q41544270-04C97CE7-D67C-4554-AEEE-9F79275A0432Q41996825-CD4B9AC8-2099-4DE7-93AA-4EEAD3A77A26Q42028017-B618F3B5-BB41-495F-90DF-51D162F844F7Q42242203-518A1E49-E3A5-4FCA-9F43-7FACB3B02257Q47549125-236D6E63-9834-4872-B478-B3B44A567B72Q51267918-BA6B2D20-A80E-4D1B-85B6-0E5F728D2D2FQ53170357-09D46511-2B94-49CB-94DA-9ADC811351BD
P2860
A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A prolyl oligopeptidase inhibi ...... models of Parkinson's disease.
@en
A prolyl oligopeptidase inhibi ...... models of Parkinson's disease.
@nl
type
label
A prolyl oligopeptidase inhibi ...... models of Parkinson's disease.
@en
A prolyl oligopeptidase inhibi ...... models of Parkinson's disease.
@nl
prefLabel
A prolyl oligopeptidase inhibi ...... models of Parkinson's disease.
@en
A prolyl oligopeptidase inhibi ...... models of Parkinson's disease.
@nl
P2093
P2860
P1476
A prolyl oligopeptidase inhibi ...... models of Parkinson's disease.
@en
P2093
A M Lambeir
J A García-Horsman
M J Hannula
P T Männistö
P Van Der Veken
R Van Elzen
V Baekelandt
P2860
P304
P356
10.1111/J.1476-5381.2012.01846.X
P407
P577
2012-06-01T00:00:00Z